This comprehensive analysis delves into Pfizer’s current position, future prospects, and the factors shaping its stock outlook. Financial Performance and 2025 Guidance ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer’s financial outlook for 2025 has been a focal point for investors and analysts. The company has maintained its revenue guidance for fiscal year 2025 at $61.0-64.0 billion, with the COVID ...

Pfizer Inc. (NYSE: PFE), a global biopharmaceutical giant with a market capitalization of $139.52 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and why it is a Buy.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $135.18, with a high estimate of $155.00 and a low estimate of $110.00. Highlighting a 3.58% ...

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILINGPoster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour ...

Common use cases of AI in the supply chain illustrate the benefits for companies of integrating AI into their operations. Attorneys supporting the supply chain function can similarly use generative AI ...